BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Obesity clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for obesity: 500 (179 sponsors; 195 newly posted in the last 180 days, 11 stopped in the last 180 days; 48 new-entrant sponsors). Momentum score 38.5, rank 1 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 3, Phase 1 158, Phase 2 91, Phase 3 155, Phase 4 8, N/A 85.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Eli Lilly and Company LLY | 59 | P3 35, P1 13, P2 7, P4 4 | 17 | 8 |
| Novo Nordisk A/S NVO | 70 | P3 26, P1 27, NA 11, P2 5, P4 1 | 25 | 14 |
| Pfizer PFE | 20 | P3 13, P1 6, P2 1 | 15 | 5 |
| Amgen AMGN | 18 | P3 12, P1 4, P2 2 | 7 | 5 |
| Hoffmann-La Roche | 12 | P3 7, P1 3, P2 2 | 5 | 2 |
| AstraZeneca AZN | 13 | P1 5, P3 6, P2 2 | 8 | 5 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | 12 | P1 5, P2 2, P3 5 | 5 | 8 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 11 | P1 4, P3 5, P2 2 | 3 | 2 |
| Innovent Biologics (Suzhou) Co. Ltd. | 9 | P3 4, P2 2, P1 3 | 3 | 2 |
| Hangzhou Sciwind Biosciences Co., Ltd. | 8 | P2 3, P1 1, P3 4 | 4 | 3 |
| Viking Therapeutics, Inc. VKTX | 6 | P3 4, P1 2 | 4 | 1 |
| Boehringer Ingelheim | 11 | P1 7, P2 1, P3 3 | 8 | 4 |
| Regeneron Pharmaceuticals REGN | 9 | P3 3, P2 5, P1 1 | 4 | 2 |
| Kailera KLRA | 7 | P2 2, P1 2, P3 3 | 2 | 2 |
| The United Bio-Technology (Hengqin) Co., Ltd. | 7 | P1 3, P3 3, P2 1 | 6 | 2 |
| Gan & Lee Pharmaceuticals. | 4 | P1 1, P3 3 | 1 | 0 |
| Ascletis Pharma (China) Co., Limited new entrant | 5 | P1 3, P3 2 | 5 | 1 |
| Rhythm Pharmaceuticals, Inc. RYTM | 5 | P2 3, P3 2 | 0 | 2 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics new entrant | 2 | P3 2 | 2 | 0 |
| Harmony Biosciences Management, Inc. HRMY | 2 | P3 2 | 0 | 1 |
| Beijing QL Biopharmaceutical Co.,Ltd | 8 | P1 5, P2 2, P3 1 | 3 | 5 |
| Shanghai Minwei Biotechnology Co., Ltd | 8 | P1 5, P3 1, P2 2 | 6 | 0 |
| BrightGene Bio-Medical Technology Co., Ltd. new entrant | 3 | P2 2, P3 1 | 3 | 1 |
| Chendu DIAO Pharmaceutical Group CO., LTD. new entrant | 3 | P1 2, P3 1 | 3 | 2 |
| Guangdong Raynovent Biotech Co., Ltd | 3 | P2 1, P1 1, P3 1 | 0 | 0 |
New-entrant sponsors: Ascletis Pharma (China) Co., Limited, Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, BrightGene Bio-Medical Technology Co., Ltd., Chendu DIAO Pharmaceutical Group CO., LTD..
Recently stopped trials
- NCT02893618 Essentialis, Inc. - withdrawn: Sponsor decision A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Control
- NCT05532020 Soleno Therapeutics, Inc. - withdrawn: Company Decision An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities
- NCT07553299 Verdiva Bio Dev Limited - terminated: The Study Sponsor made a business decision not to continue the study. The decision was not based on safety findings. A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweig
- NCT07152002 Eli Lilly and Company - terminated: Sponsor Decision A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
- NCT07030868 Eli Lilly and Company - terminated: Study terminated for strategic business reasons A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
- NCT06894498 Boston Scientific Corporation - terminated: Business decision. Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
- NCT07190794 Boston Scientific Corporation - terminated: Business decision RESCUE: Discontinuation of GLP-1
- NCT03686657 ARKAY Therapeutics - withdrawn: Clinical stage asset and the sponsorship have been acquired by Myopharm Limited. Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients
- NCT07357766 Novo Nordisk A/S - withdrawn: The study is withdrawn due to strategic reasons. A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
- NCT06828861 Aardvark Therapeutics, Inc. - terminated: Due to operational and regulatory considerations. ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
- NCT07197034 Aardvark Therapeutics, Inc. - terminated: Due to operational and regulatory considerations. The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-20 est. | P2 | Skye Bioscience, Inc. SKYE | NCT06577090 Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo | Obesity | active not recruiting | 136 |
| 2026-11-30 est. | P2 | BioAge Labs, Inc. BIOA | NCT07656727 A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors | Obesity and Cardiovascular Risk | active not recruiting | 160 |
| 2026-12 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT06820099 Study on the Efficacy and Safety of HRS-7535 in Patients With Mild Decrease in Ejection Fraction/Preserved Ejection Fraction Heart Failure and Obesity | Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesi | recruiting | 225 |
| 2026-12 est. | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06974851 A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | Bstructive Sleep Apnea (OSA) and Obesity | recruiting | 140 |
| 2026-12 est. | P3 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06994650 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With O | Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy | active not recruiting | 144 |
| 2026-12-01 est. | P3 | Vanda Pharmaceuticals VNDA | NCT07446439 A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | Nausea and Vomiting; Obesity | recruiting | 280 |
| 2026-12-12 est. | P2 | Beijing QL Biopharmaceutical Co.,Ltd | NCT07230132 Efficacy and Safety of ZT006 in Overweight and Obese Participants | Overweight , Obesity | active not recruiting | 184 |
| 2026-12-14 est. | P2 | Novo Nordisk A/S NVO | NCT07184632 A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity | Overweight; Obesity | active not recruiting | 224 |
| 2026-12-31 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06884293 A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) | active not recruiting | 479 |
| 2026-12-31 est. | P3 | HK inno.N Corporation | NCT07192263 Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus | Obesity &Amp; Overweight | not yet recruiting | 300 |
| 2027-01 est. | P2 | Hanmi Pharmaceutical Company Limited HAFC | NCT07205900 Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus | Obese; Obesity | active not recruiting | 267 |
| 2027-01-05 est. | P1/P2 | Hangzhou Sciwind Biosciences Co., Ltd. | NCT07243171 A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overwe | Overweight and/or Obesity; Weight Management | recruiting | 126 |
| 2027-01-14 est. | P2 | Novo Nordisk A/S NVO | NCT07395687 A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity | Overweight; Obesity | recruiting | 333 |
| 2027-01-21 est. | P3 | Amgen AMGN | NCT06858839 Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Obesity | active not recruiting | 3853 |
| 2027-01-21 est. | P3 | Amgen AMGN | NCT06858878 Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | active not recruiting | 1105 |
| 2027-01-29 est. | P1/P2 | AstraZeneca AZN | NCT06151964 A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | Overweight and Obesity | active not recruiting | 166 |
| 2027-01-31 est. | P2 | NeuroBiogen Co., Ltd | NCT07009171 Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients | Overweight; Obesity; Obese Patients | recruiting | 75 |
| 2027-02 est. | P3 | Eli Lilly and Company LLY | NCT06672549 A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | Obesity; Overweight | recruiting | 125 |
| 2027-02 est. | P1/P2 | Arrowhead Pharmaceuticals ARWR | NCT06937203 A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Obesity; Diabetes Mellitus, Type 2 | recruiting | 150 |
| 2027-02 est. | P2 | Antag Therapeutics | NCT07724340 A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweigh | Adults With Overweight/Obesity and Type 2 Diabetes | active not recruiting | 150 |
| 2027-02-01 est. | P2 | AB Biotics, SA | NCT07193927 Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Fatty Liver Disease, Nonalcoholic; | recruiting | 60 |
| 2027-02-04 est. | P2 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07521631 Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | Obesity | recruiting | 372 |
| 2027-02-05 est. | P2 | EktaH | NCT07882654 A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBESE ADULTS. | Obesity / Overweight; Obesity (BMI Equal to or >30) | not yet recruiting | 31 |
| 2027-02-14 est. | P3 | Hudson Biotech | NCT07481747 Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities | recruiting | 2539 |
| 2027-02-14 est. | P2 | Hudson Biotech | NCT07505745 MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity | Prediabetes; Insulin Resistance; Overweight/Obesity | recruiting | 120 |
| 2027-02-15 est. | P1/P2 | Ikaria Bioscience Pty Ltd | NCT07245771 Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination | Obesity &Amp; Overweight | recruiting | 104 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-13 est. | P2 | Regeneron Pharmaceuticals REGN | NCT07431086 Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US | Overweight or Obesity | active not recruiting | 120 |
| 2026-11-03 | P2 | Rhythm Pharmaceuticals, Inc. RYTM | NCT06772597 A Study of Setmelanotide in Patients With Prader-Willi Syndrome | Prader-Willi Syndrome; Obesity; Hyperphagia | active not recruiting | 18 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight | active not recruiting | 465 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight | active not recruiting | 905 |
| 2026-11 est. | P2 | KeyBioscience AG | NCT06833749 Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis | Osteoarthritis in the Knee; Obesity | recruiting | 600 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06662383 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Obesity | active not recruiting | 800 |
| 2026-10-23 est. | P2 | AstraZeneca AZN | NCT07017179 This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight | Obesity/Overweight | active not recruiting | 16 |
| 2026-10-15 est. | P2 | Eccogene | NCT07505303 MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial | Adult Obesity; Weight Management | active not recruiting | 151 |
| 2026-10 est. | P2 | Shanghai Minwei Biotechnology Co., Ltd | NCT07791537 Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight | Overweight , Obesity | active not recruiting | 125 |
| 2026-09-30 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07000955 Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Obesity | active not recruiting | 98 |
| 2026-09-29 | P1/P2 | Pfizer PFE | NCT06924320 A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes | Obesity and Obesity-related Medical Conditions | completed | 201 |
| 2026-09-24 est. | P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06862908 A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity | Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced E | active not recruiting | 141 |
| 2026-09-22 | P3 | Gan & Lee Pharmaceuticals. | NCT07292441 Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss | Overweight or Obesity | completed | 224 |
| 2026-09-20 est. | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07279194 Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes | Obesity & Overweight | recruiting | 825 |
| 2026-09-18 | P2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | NCT07400588 Aleniglipron Phase 2 in Type 2 Diabetes Mellitus | Obese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Loss | completed | 58 |
| 2026-09-11 | P2 | Verdiva Bio Dev Limited | NCT07553299 A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity; Overweight; Weight Maintenance | terminated | 8 |
| 2026-09-09 | P2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | NCT07169942 Aleniglipron Phase 2 Body Composition Study | Obesity, Overweight, or Chronic Weight Management | completed | 71 |
| 2026-09-03 | P2 | Hoffmann-La Roche | NCT06965413 A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants W | Obesity; Overweight; Overweight With One Weight Related Comorbidity | active not recruiting | 285 |
| 2026-09 est. | P2 | Shanghai Minwei Biotechnology Co., Ltd | NCT07804797 Phase 2 Study of MWN109 Tablet for Weight-Loss Maintenance in Participants With Overweight or Obesity | Overweight , Obesity | active not recruiting | 71 |
| 2026-09 est. | P2 | Biohaven Therapeutics Ltd. BHVN | NCT07281495 Taldefgrobep Alfa in Adults With Overweight and Obesity | Obesity; Overweight | active not recruiting | 150 |
| 2026-08-21 | P2 | NodThera Ltd. (a Rezera company) | NCT07220629 Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2) | Obesity | completed | 82 |
| 2026-08-13 | P2 | Zealand Pharma ZEAL.CO | NCT06926842 Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2) | Overweight; Type 2 Diabetes; Obesity | completed | 221 |
| 2026-08-01 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07469800 Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity | Overweight; Obesity; Hypertensive | recruiting | 336 |
| 2026-07-23 | P2 | Verdiva Bio Dev Limited | NCT07281937 A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity; Overweight | completed | 206 |
| 2026-07-21 | P3 | Eli Lilly and Company LLY | NCT06649045 A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight | OSA; Overweight or Obesity | completed | 712 |
| 2026-07-15 est. | P2 | Immunis, Inc. | NCT06600581 Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness | Muscle Performance; Sarcopenic Obesity | active not recruiting | 55 |
| 2026-07-09 | P2 | Shanghai Minwei Biotechnology Co., Ltd | NCT07791524 Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity | Overweight , Obesity | completed | 255 |
| 2026-07-06 | P2 | Eli Lilly and Company LLY | NCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D | completed | 134 |
| 2026-07-01 | P2 | Eli Lilly and Company LLY | NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight W | Obesity; Overweight | completed | 367 |
| 2026-07 est. | P2 | Aphaia Pharma US LLC | NCT07008456 A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Comp | Obese With Comorbidities; Obese Patients (BMI ≥ 30 kg/m²) | recruiting | 102 |
| 2026-06-24 | P3 | Rhythm Pharmaceuticals, Inc. RYTM | NCT06596135 Open-Label Extension Study of Setmelanotide | Obesity Associated With Defects in Leptin-melanocortin Pathway | completed | 28 |
| 2026-06-16 | P2 | Regeneron Pharmaceuticals REGN | NCT06299098 A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weig | Obesity | completed | 1005 |
| 2026-06-16 | P3 | Eli Lilly and Company LLY | NCT05929079 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight | Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea | completed | 1152 |
| 2026-06-15 est. | P3 | Guangdong Raynovent Biotech Co., Ltd | NCT06893016 Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight | Obesity | recruiting | 640 |
| 2026-06-02 | P3 | Eli Lilly and Company LLY | NCT06075667 A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity; Overweight | active not recruiting | 160 |
| 2026-06-01 | P3 | Boehringer Ingelheim | NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | Obesity | completed | 5530 |
| 2026-05-30 est. | P3 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT06885021 Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults | Overweight and Obesity | not yet recruiting | 780 |
| 2026-05-30 est. | P3 | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | NCT06633783 A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy® | Obesity | unknown | 370 |
| 2026-05-29 | P2 | Carmot Therapeutics, Inc. | NCT06628362 A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus | Overweight or Obese; Type 2 Diabetes Mellitus (T2DM) | completed | 447 |
| 2026-05-27 | P2 | NodThera Ltd. (a Rezera company) | NCT07055516 Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus | Obesity and Type 2 Diabetes | completed | 176 |
| 2026-05-26 | P2 | AstraZeneca AZN | NCT06851858 Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor A | Endocrinology; Diabetes, Type II; Obesity | completed | 69 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "obesity"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.